               SEQUENCE LISTING

<110> Atlas Biotechnology SA

<120> Alpha-1-antitrypsin (AAT) in the treatment and/or prevention of neurological disorders

<130> AE3184 PCT BS

<150> EP22168622.3
<151> 2022-04-14
<150> EP21206096.6
<151> 2021-11-02
<150> PCT/EP2021/061597
<151> 2021-05-03

<160> 8

<170> BiSSAP 1.3.6

<210> 1
<211> 418
<212> PRT
<213> Homo sapiens


<220> 
<223> AAT

<400> 1
Met Pro Ser Ser Val Ser Trp Gly Ile Leu Leu Leu Ala Gly Leu Cys 
1               5                   10                  15      
Cys Leu Val Pro Val Ser Leu Ala Glu Asp Pro Gln Gly Asp Ala Ala 
            20                  25                  30          
Gln Lys Thr Asp Thr Ser His His Asp Gln Asp His Pro Thr Phe Asn 
        35                  40                  45              
Lys Ile Thr Pro Asn Leu Ala Glu Phe Ala Phe Ser Leu Tyr Arg Gln 
    50                  55                  60                  
Leu Ala His Gln Ser Asn Ser Thr Asn Ile Phe Phe Ser Pro Val Ser 
65                  70                  75                  80  
Ile Ala Thr Ala Phe Ala Met Leu Ser Leu Gly Thr Lys Ala Asp Thr 
                85                  90                  95      
His Asp Glu Ile Leu Glu Gly Leu Asn Phe Asn Leu Thr Glu Ile Pro 
            100                 105                 110         
Glu Ala Gln Ile His Glu Gly Phe Gln Glu Leu Leu Arg Thr Leu Asn 
        115                 120                 125             
Gln Pro Asp Ser Gln Leu Gln Leu Thr Thr Gly Asn Gly Leu Phe Leu 
    130                 135                 140                 
Ser Glu Gly Leu Lys Leu Val Asp Lys Phe Leu Glu Asp Val Lys Lys 
145                 150                 155                 160 
Leu Tyr His Ser Glu Ala Phe Thr Val Asn Phe Gly Asp Thr Glu Glu 
                165                 170                 175     
Ala Lys Lys Gln Ile Asn Asp Tyr Val Glu Lys Gly Thr Gln Gly Lys 
            180                 185                 190         
Ile Val Asp Leu Val Lys Glu Leu Asp Arg Asp Thr Val Phe Ala Leu 
        195                 200                 205             
Val Asn Tyr Ile Phe Phe Lys Gly Lys Trp Glu Arg Pro Phe Glu Val 
    210                 215                 220                 
Lys Asp Thr Glu Glu Glu Asp Phe His Val Asp Gln Val Thr Thr Val 
225                 230                 235                 240 
Lys Val Pro Met Met Lys Arg Leu Gly Met Phe Asn Ile Gln His Cys 
                245                 250                 255     
Lys Lys Leu Ser Ser Trp Val Leu Leu Met Lys Tyr Leu Gly Asn Ala 
            260                 265                 270         
Thr Ala Ile Phe Phe Leu Pro Asp Glu Gly Lys Leu Gln His Leu Glu 
        275                 280                 285             
Asn Glu Leu Thr His Asp Ile Ile Thr Lys Phe Leu Glu Asn Glu Asp 
    290                 295                 300                 
Arg Arg Ser Ala Ser Leu His Leu Pro Lys Leu Ser Ile Thr Gly Thr 
305                 310                 315                 320 
Tyr Asp Leu Lys Ser Val Leu Gly Gln Leu Gly Ile Thr Lys Val Phe 
                325                 330                 335     
Ser Asn Gly Ala Asp Leu Ser Gly Val Thr Glu Glu Ala Pro Leu Lys 
            340                 345                 350         
Leu Ser Lys Ala Val His Lys Ala Val Leu Thr Ile Asp Glu Lys Gly 
        355                 360                 365             
Thr Glu Ala Ala Gly Ala Met Phe Leu Glu Ala Ile Pro Met Ser Ile 
    370                 375                 380                 
Pro Pro Glu Val Lys Phe Asn Lys Pro Phe Val Phe Leu Met Ile Glu 
385                 390                 395                 400 
Gln Asn Thr Lys Ser Pro Leu Phe Met Gly Lys Val Val Asn Pro Thr 
                405                 410                 415     
Gln Lys 
        

<210> 2
<211> 44
<212> PRT
<213> Artificial Sequence


<220> 
<223> C-terminal AAT sequence 374-418

<400> 2
Met Phe Leu Glu Ala Ile Pro Met Ser Ile Pro Pro Glu Val Lys Phe 
1               5                   10                  15      
Asn Lys Pro Phe Val Phe Leu Met Ile Glu Gln Asn Thr Lys Ser Pro 
            20                  25                  30          
Leu Phe Met Gly Lys Val Val Asn Pro Thr Gln Lys 
        35                  40                  

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> Fluorogenic peptides derived from SARS-CoV-2 spike

<400> 3
His Thr Val Ser Leu Leu Arg Ser Thr Ser Gln 
1               5                   10      

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> Fluorogenic peptides derived from SARS-CoV-2 spike

<400> 4
Thr Asn Ser Pro Arg Arg Ala Arg Ser Val Ala 
1               5                   10      

<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence


<220> 
<223> HIV-TAT 48-57 peptide

<400> 5
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   10  

<210> 6
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> FHV-coat 35-49 peptide

<400> 6
Arg Arg Arg Arg Asn Arg Thr Arg Arg Asn Arg Arg Arg Val Arg 
1               5                   10                  15  

<210> 7
<211> 13
<212> PRT
<213> Artificial Sequence


<220> 
<223> HTLV-II Rex 4-16 peptide

<400> 7
Thr Arg Arg Gln Arg Thr Arg Arg Ala Arg Arg Asn Arg 
1               5                   10              

<210> 8
<211> 19
<212> PRT
<213> Artificial Sequence


<220> 
<223> BMV gag 7-25 peptide

<400> 8
Lys Met Thr Arg Ala Gln Arg Arg Ala Ala Ala Arg Arg Asn Arg Trp 
1               5                   10                  15      
Thr Ala Arg 
            

